Vera Therapeutics, Inc. $VERA Stock Position Increased by Armistice Capital LLC

Armistice Capital LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 22.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 653,796 shares of the company’s stock after buying an additional 117,796 shares during the quarter. Armistice Capital LLC’s holdings in Vera Therapeutics were worth $33,108,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Vera Therapeutics in the 4th quarter worth $46,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Vera Therapeutics in the 4th quarter worth $71,000. Quantbot Technologies LP bought a new stake in shares of Vera Therapeutics in the 2nd quarter worth $51,000. Finally, Sandia Investment Management LP bought a new stake in shares of Vera Therapeutics in the 4th quarter worth $127,000. Institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on VERA shares. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a research note on Friday, May 15th. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at $7,963,174.56. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by company insiders.

Vera Therapeutics Stock Up 4.0%

Shares of Vera Therapeutics stock opened at $35.01 on Thursday. The stock’s fifty day moving average is $36.63 and its 200-day moving average is $41.52. The firm has a market capitalization of $2.51 billion, a PE ratio of -6.32 and a beta of 0.93. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 12-month low of $19.07 and a 12-month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the business earned ($0.81) earnings per share. Equities analysts anticipate that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.